Literature DB >> 30740417

FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer.

Roland Ehrenberg1, Niels Halama1.   

Abstract

Entities:  

Year:  2018        PMID： 30740417      PMCID： PMC6330626          DOI： 10.21037/atm.2018.11.22

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  17 in total

1.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Authors:  Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

Authors:  F Maindrault-Goebel; C Louvet; T André; E Carola; J P Lotz; J L Molitor; M L Garcia; V Gilles-Amar; V Izrael; M Krulik; A de Gramont
Journal:  Eur J Cancer       Date:  1999-09       Impact factor: 9.162

3.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Authors:  C Bokemeyer; I Bondarenko; J T Hartmann; F de Braud; G Schuch; A Zubel; I Celik; M Schlichting; P Koralewski
Journal:  Ann Oncol       Date:  2011-01-12       Impact factor: 32.976

4.  Immunogenic death of colon cancer cells treated with oxaliplatin.

Authors:  A Tesniere; F Schlemmer; V Boige; O Kepp; I Martins; F Ghiringhelli; L Aymeric; M Michaud; L Apetoh; L Barault; J Mendiboure; J-P Pignon; V Jooste; P van Endert; M Ducreux; L Zitvogel; F Piard; G Kroemer
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

5.  Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.

Authors:  T André; M A Bensmaine; C Louvet; E François; V Lucas; F Desseigne; K Beerblock; O Bouché; E Carola; Y Merrouche; F Morvan; G Dupont-André; A de Gramont
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

6.  High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

Authors:  F Maindrault-Goebel; A de Gramont; C Louvet; T André; E Carola; M Mabro; P Artru; V Gilles; J P Lotz; V Izrael; M Krulik
Journal:  Eur J Cancer       Date:  2001-05       Impact factor: 9.162

7.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Authors:  Jim Cassidy; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Leonard Saltz
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

8.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

9.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.

Authors:  M L Rothenberg; J V Cox; C Butts; M Navarro; Y-J Bang; R Goel; S Gollins; L L Siu; S Laguerre; D Cunningham
Journal:  Ann Oncol       Date:  2008-06-10       Impact factor: 32.976
View more
  1 in total

1.  Expression of biogenesis of ribosomes BRX1 is associated with malignant progression and prognosis in colorectal cancer.

Authors:  Jianxin Ge; Xiaoli Huang; Ping Wang; Cuihua Lu
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.